Investor Presentation Full Year 2021
135
Investor presentation Full year 2021
Novo NordiskⓇ
US insulin net prices have declined in recent years, but
vulnerable patients rely on our affordability offerings
The US population by health
insurance coverage
Private insurance schemes
| Government insurance schemes
7%
Uninsured
Net price development for Novo Nordisk
products
US Product portfolio¹ %, Change vs. Prior year
2017
2018 2019 2020
2021
•
•
Novo Nordisk insulin affordability offerings in
the US
My$99Insulin 30-day supply of a combination of
Novo Nordisk insulin products (up to 3 vials or 2
packs of pens) for USD 99
NNPI unbranded biologics fast-acting (NovologⓇ)
and premix insulin (Novolog® Mix) with 50% list price
discount vs branded versions
46%
List Price change - Avg²
Net Price change - Avg²
6.9%
5.0% 5.5% 2.3% 2.0%
-9.0% -8.6% -13.2% -16.9% -12.3%
Human insulin for about USD25/vial at national
pharmacies, including Walmart and CVS
47%
Total US Insulin portfolio %, Change vs. Prior year
2017
2018 2019 2020
2021
•
Patient Assistance Program free diabetes
medication to people in need, annual income <400%
above government defined poverty. Program
333 million people
List Price change - Avg²
Net Price change - Avg² -13.5%
expanded during COVID-19 outbreak
6.3%
4.5% 4.4% 0.2%
-14.8% -17.4% -27.7% -10.2%
0.0%
•
Immediate supply a short-term, immediate-need
program offering free insulin for those at risk of
rationing
•
Co-pay Savings Cards providing USD -100 million in
assistance in 2021 for insulin to patients
Note: Government insurance schemes cover Medicare, Medicaid and public exchanges, some of these with high deductibles Source: Centres for Medicare and Medicaid
services, office of the actuary, National Health expenditures Projections; 1 NN US Product portfolio is inclusive of Diabetes, Obesity and Biopharm products; 2% change
represents a sale weighted average list and net price for the respective calendar year compared to the sales weighted average list and net price for the prior year and is not
reflective of the magnitude of individual list price actions
•
In 2021, more than 1 million people reachedView entire presentation